Proactive Investors - Run By Investors For Investors

Medexus Pharmaceuticals plans million-share buyback to unlock shareholder value

The specialty pharmaceutical company will seek to repurchase approximately 6.8% of outstanding Medexus stock and around 10% of its public float, or a total of 1,005,333 shares
stem cell
The company's flagship product, Treosulfan, is a conditioning agent used before stem cell transplantation.

Medexus Pharmaceuticals (CVE:MDP), a specialty pharmaceutical company, announced Tuesday that it intends to make a normal course issuer bid to repurchase about a million shares of the company.

The bid represents approximately 6.8% of outstanding Medexus stock and around 10% of its public float, or a total of 1,005,333 shares.

READ: Aequus Pharmaceuticals brings in $2.35 million after closing offering

The Montreal-based company is working with Canaccord Genuity Corp on an automatic securities purchase plan to complete the share buyback. Medexus has submitted a notice of its plan to the TSX Venture Exchange for approval.

The Medexus board said in a statement that it believes the market price of the shares may not fully reflect their underlying value, and that the proposed plan is in the best interest of the company and a desirable use of corporate funds.

The company also noted that the repurchase plan is advantageous to remaining Medexus shareholders and will increase the proportionate value of each shareholder.

Shares will be purchased on the open market through the TSX Venture Exchange or by any other means permitted by the exchange. The repurchase price will be the prevailing market price at the time of purchase.

The company anticipates the bid to commence by May 16 and will conclude by May 15, 2020 or once the company has purchased the maximum number of shares outlined in the bid. Medexus may also provide a notice of termination to the exchange at any time.

Commercial platform

Medexus is a specialty pharmaceutical company with a North American commercial platform, focused on auto-immune disease and pediatrics.

It recently received Health Canada authorization to distribute Treosulfan through a special access program.

Treosulfan is a conditioning agent used before stem cell transplantation.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full MDP profile View Profile

Medexus Pharmaceuticals Inc Timeline

Related Articles

Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use